AI summary · may contain errors
Unsupervised clustering of 2,035 anti-synthetase syndrome (ASyS) cases in the CLASS project database identified three ASyS phenotypic subgroups, including an ILD-predominant group (n = 581).
- Open access
Moving in Arthritis & Rheumatology, JAMA Neurology, Annals of the Rheumatic Diseases, medRxiv, The Lancet Rheumatology, JAMA Dermatology, Journal of Investigative Dermatology and Nature Reviews Rheumatology.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Unsupervised clustering of 2,035 anti-synthetase syndrome (ASyS) cases in the CLASS project database identified three ASyS phenotypic subgroups, including an ILD-predominant group (n = 581).
AI summary · may contain errors
Immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) is the most common rheumatic immune-related adverse event and is marked by a distinct clonal expansion of CD8+ T cells.
AI summary · may contain errors
Low-dose blinatumomab given as 2 cycles by continuous intravenous infusion in 2 patients (anti-Mi-2-positive dermatomyositis and refractory ANCA-associated vasculitis) showed rapid T-cell activation and B-cell depletion with clinical improvement.
AI summary · may contain errors
Add-on intravenous immunoglobulin (IVIG) given at 0, 4, and 8 weeks improves myositis activity at week 12 in newly diagnosed adult idiopathic inflammatory myopathies, raising Total Improvement Score to 60.0 vs 42.5 with P=.01.
AI summary · may contain errors
Low-dose interleukin-2 restores CD25hi regulatory T cells in patients with active polymyositis/dermatomyositis, with reduced Treg-IL-2 axis markers compared with healthy controls.
AI summary · may contain errors
Inebilizumab reduced exacerbation risk in randomized phase 3 myasthenia gravis (gMG) patients, with hazard ratios of 0.41 by week 26 overall.
AI summary · may contain errors
A 65-year-old man with cavin-4 IgG rippling muscle disease achieved complete remission after rituximab therapy.
AI summary · may contain errors
Activating PRKD2 missense variants were found in two families with systemic sclerosis, and they increased kinase activation and TCR signaling in heterozygous knock-in Jurkat cells.
Journals this month
Topics moving, week to 17 Nov 2026
By field